172 related articles for article (PubMed ID: 23666780)
1. In vivo protection of activated Tyr22-dihydrofolate reductase gene-modified canine T lymphocytes from methotrexate.
Gori JL; Beard BC; Williams NP; Ironside C; Swanson D; Scott McIvor R; Kiem HP
J Gene Med; 2013; 15(6-7):233-41. PubMed ID: 23666780
[TBL] [Abstract][Full Text] [Related]
2. In vivo selection of human embryonic stem cell-derived cells expressing methotrexate-resistant dihydrofolate reductase.
Gori JL; Tian X; Swanson D; Gunther R; Shultz LD; McIvor RS; Kaufman DS
Gene Ther; 2010 Feb; 17(2):238-49. PubMed ID: 19829316
[TBL] [Abstract][Full Text] [Related]
3. Transgenic mice expressing the tyr22 variant of murine DHFR: protection of transgenic marrow transplant recipients from lethal doses of methotrexate.
James RI; May C; Vagt MD; Studebaker R; McIvor RS
Exp Hematol; 1997 Nov; 25(12):1286-95. PubMed ID: 9357973
[TBL] [Abstract][Full Text] [Related]
4. Protection of mice from methotrexate toxicity by ex vivo transduction using lentivirus vectors expressing drug-resistant dihydrofolate reductase.
Gori JL; Podetz-Pedersen K; Swanson D; Karlen AD; Gunther R; Somia NV; McIvor RS
J Pharmacol Exp Ther; 2007 Sep; 322(3):989-97. PubMed ID: 17586722
[TBL] [Abstract][Full Text] [Related]
5. Mild preconditioning and low-level engraftment confer methotrexate resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate reductase activity.
James RI; Warlick CA; Diers MD; Gunther R; McIvor RS
Blood; 2000 Aug; 96(4):1334-41. PubMed ID: 10942375
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo.
Zhao RC; McIvor RS; Griffin JD; Verfaillie CM
Blood; 1997 Dec; 90(12):4687-98. PubMed ID: 9389683
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate preconditioning allows sufficient engraftment to confer drug resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate reductase activity.
Belur LR; James RI; May C; Diers MD; Swanson D; Gunther R; McIvor RS
J Pharmacol Exp Ther; 2005 Aug; 314(2):668-74. PubMed ID: 15857949
[TBL] [Abstract][Full Text] [Related]
8. Dihydrofolate Reductase and Thymidylate Synthase Transgenes Resistant to Methotrexate Interact to Permit Novel Transgene Regulation.
Rushworth D; Mathews A; Alpert A; Cooper LJ
J Biol Chem; 2015 Sep; 290(38):22970-6. PubMed ID: 26242737
[TBL] [Abstract][Full Text] [Related]
9. Retrovirally mediated gene transfer of Arg22 and Tyr22 forms of dihydrofolate reductase into the hematopoietic cell line K562: a comparison of methotrexate resistance.
Braun SE; McIvor RS; Davidson AS; Hanna M; Traycoff CM; Berebetsky DA; Gonin R; Broxmeyer HE; Cornetta K
Cancer Gene Ther; 1997; 4(1):26-32. PubMed ID: 9012448
[TBL] [Abstract][Full Text] [Related]
10. Efficient protection from methotrexate toxicity and selection of transduced human hematopoietic cells following gene transfer of dihydrofolate reductase mutants.
Meisel R; Bardenheuer W; Strehblow C; Sorg UR; Elmaagacli A; Seeber S; Flasshove M; Moritz T
Exp Hematol; 2003 Dec; 31(12):1215-22. PubMed ID: 14662327
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate supports in vivo selection of human embryonic stem cell derived-hematopoietic cells expressing dihydrofolate reductase.
Gori JL; McIvor RS; Kaufman DS
Bioeng Bugs; 2010; 1(6):434-6. PubMed ID: 21468213
[TBL] [Abstract][Full Text] [Related]
12. Selective expression of methotrexate-resistant dihydrofolate reductase (DHFR) activity in mice transduced with DHFR retrovirus and administered methotrexate.
Vinh DB; McIvor RS
J Pharmacol Exp Ther; 1993 Nov; 267(2):989-96. PubMed ID: 8246174
[TBL] [Abstract][Full Text] [Related]
13. Comparison of methotrexate resistance conferred by a mutated dihydrofolate reductase (DHFR) cDNA in two different retroviral vectors.
Takebe N; Nakahara S; Zhao SC; Adhikari D; Ural AU; Iwamoto M; Banerjee D; Bertino JR
Cancer Gene Ther; 2000 Jun; 7(6):910-9. PubMed ID: 10880023
[TBL] [Abstract][Full Text] [Related]
14. Engineering human T cells for resistance to methotrexate and mycophenolate mofetil as an in vivo cell selection strategy.
Jonnalagadda M; Brown CE; Chang WC; Ostberg JR; Forman SJ; Jensen MC
PLoS One; 2013; 8(6):e65519. PubMed ID: 23755242
[TBL] [Abstract][Full Text] [Related]
15. Drug-resistant dihydrofolate reductases: generation, expression and therapeutic application.
McIvor RS
Bone Marrow Transplant; 1996 Dec; 18 Suppl 3():S50-4. PubMed ID: 8971409
[TBL] [Abstract][Full Text] [Related]
16. Long-term exposure to methotrexate induces immunophenotypic changes, decreased methotrexate uptake and increased dihydrofolate gene copy number in Jurkat T cells.
Hall MJ; Lawrence DA; Lansiedel JC; Walsh AC; Comstock LL; Kremer JM
Int J Immunopharmacol; 1997; 19(11-12):709-20. PubMed ID: 9669212
[TBL] [Abstract][Full Text] [Related]
17. Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene.
Takebe N; Zhao SC; Adhikari D; Mineishi S; Sadelain M; Hilton J; Colvin M; Banerjee D; Bertino JR
Mol Ther; 2001 Jan; 3(1):88-96. PubMed ID: 11162315
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate selection of long-term culture initiating cells following transduction of CD34(+) cells with a retrovirus containing a mutated human dihydrofolate reductase gene.
Takebe N; Xu LC; MacKenzie KL; Bertino JR; Moore MA
Cancer Gene Ther; 2002 Mar; 9(3):308-20. PubMed ID: 11896448
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemistry of dihydrofolate reductase in methotrexate-sensitive and -resistant human cell lines by flow cytometry: a comparison with the cytochemical tetrazolium salt method.
Nano R; Gerzeli G; Morandi C; Arisi C
Acta Histochem; 1992; 93(1):290-7. PubMed ID: 1529671
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate exacerbates tumor progression in a murine model of chronic myeloid leukemia.
Sweeney CL; Diers MD; Frandsen JL; Gunther R; Verfaillie CM; McIvor RS
J Pharmacol Exp Ther; 2002 Mar; 300(3):1075-84. PubMed ID: 11861818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
